Zhuoying Chen, Quan Wang, Yao Yao Yan, Dalong Jin, Yumeng Wang, Xing Xing Zhang, Xin Hua Liu
{"title":"发现治疗急性髓性白血病的新型强效 CDK8 抑制剂。","authors":"Zhuoying Chen, Quan Wang, Yao Yao Yan, Dalong Jin, Yumeng Wang, Xing Xing Zhang, Xin Hua Liu","doi":"10.1080/14756366.2024.2305852","DOIUrl":null,"url":null,"abstract":"<p><p>It has been reported that CDK8 plays a key role in acute myeloid leukaemia. Here, a total of 40 compounds were rational designed and synthesised based on the previous SAR. Among them, compound <b>12</b> (<i>3-(3-(furan-3-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl)benzamide</i>) showed the most potent inhibiting activity against CDK8 with an IC<sub>50</sub> value of 39.2 ± 6.3 nM and anti AML cell proliferation activity (molm-13 GC<sub>50</sub> = 0.02 ± 0.01 <i>μ</i>M, MV4-11 GC<sub>50</sub> = 0.03 ± 0.01 <i>μ</i>M). Mechanistic studies revealed that this compound <b>12</b> could inhibit the phosphorylation of STAT-1 and STAT-5. Importantly, compound <b>12</b> showed relative good bioavailability (<i>F</i> = 38.80%) and low toxicity <i>in vivo</i>. This study has great significance for the discovery of more efficient CDK8 inhibitors and the development of drugs for treating AML in the future.</p>","PeriodicalId":15769,"journal":{"name":"Journal of Enzyme Inhibition and Medicinal Chemistry","volume":null,"pages":null},"PeriodicalIF":5.6000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10810651/pdf/","citationCount":"0","resultStr":"{\"title\":\"Discovery of novel and potent CDK8 inhibitors for the treatment of acute myeloid leukaemia.\",\"authors\":\"Zhuoying Chen, Quan Wang, Yao Yao Yan, Dalong Jin, Yumeng Wang, Xing Xing Zhang, Xin Hua Liu\",\"doi\":\"10.1080/14756366.2024.2305852\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>It has been reported that CDK8 plays a key role in acute myeloid leukaemia. Here, a total of 40 compounds were rational designed and synthesised based on the previous SAR. Among them, compound <b>12</b> (<i>3-(3-(furan-3-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl)benzamide</i>) showed the most potent inhibiting activity against CDK8 with an IC<sub>50</sub> value of 39.2 ± 6.3 nM and anti AML cell proliferation activity (molm-13 GC<sub>50</sub> = 0.02 ± 0.01 <i>μ</i>M, MV4-11 GC<sub>50</sub> = 0.03 ± 0.01 <i>μ</i>M). Mechanistic studies revealed that this compound <b>12</b> could inhibit the phosphorylation of STAT-1 and STAT-5. Importantly, compound <b>12</b> showed relative good bioavailability (<i>F</i> = 38.80%) and low toxicity <i>in vivo</i>. This study has great significance for the discovery of more efficient CDK8 inhibitors and the development of drugs for treating AML in the future.</p>\",\"PeriodicalId\":15769,\"journal\":{\"name\":\"Journal of Enzyme Inhibition and Medicinal Chemistry\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":5.6000,\"publicationDate\":\"2024-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10810651/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Enzyme Inhibition and Medicinal Chemistry\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/14756366.2024.2305852\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/23 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"BIOCHEMISTRY & MOLECULAR BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Enzyme Inhibition and Medicinal Chemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14756366.2024.2305852","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/23 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
Discovery of novel and potent CDK8 inhibitors for the treatment of acute myeloid leukaemia.
It has been reported that CDK8 plays a key role in acute myeloid leukaemia. Here, a total of 40 compounds were rational designed and synthesised based on the previous SAR. Among them, compound 12 (3-(3-(furan-3-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl)benzamide) showed the most potent inhibiting activity against CDK8 with an IC50 value of 39.2 ± 6.3 nM and anti AML cell proliferation activity (molm-13 GC50 = 0.02 ± 0.01 μM, MV4-11 GC50 = 0.03 ± 0.01 μM). Mechanistic studies revealed that this compound 12 could inhibit the phosphorylation of STAT-1 and STAT-5. Importantly, compound 12 showed relative good bioavailability (F = 38.80%) and low toxicity in vivo. This study has great significance for the discovery of more efficient CDK8 inhibitors and the development of drugs for treating AML in the future.
期刊介绍：
Journal of Enzyme Inhibition and Medicinal Chemistry publishes open access research on enzyme inhibitors, inhibitory processes, and agonist/antagonist receptor interactions in the development of medicinal and anti-cancer agents.
Journal of Enzyme Inhibition and Medicinal Chemistry aims to provide an international and interdisciplinary platform for the latest findings in enzyme inhibition research.
The journal’s focus includes current developments in:
Enzymology;
Cell biology;
Chemical biology;
Microbiology;
Physiology;
Pharmacology leading to drug design;
Molecular recognition processes;
Distribution and metabolism of biologically active compounds.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
